Tecentriq & Avastin (atezolizumab & bevacizumab)

pCPA File Number: 21390

Negotiation Status:

Concluded with an LOI

Indication(s):

Unresectable or metastatic hepatocellular carcinoma (HCC) in adult patients who require systemic therapy

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0217-000

pCPA Engagement Letter Issued:

2021-03-26

Negotiation Process Concluded:

2021-10-14